ACLX
Arcellx Inc

429
Loading...
Loading...
News
all
press releases
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
More News
News Placeholder
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.
investing.com·3mo ago
News Placeholder
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
chainwire·4mo ago
News Placeholder
Sarepta, other biotech stocks tumble as FDA appoints new CBER director
Investing.com -- Shares of several biotech companies experienced significant declines in Tuesday’s trading session following the announcement of Dr. Vinay Prasad as the new director of the Center for Biologics Evaluation and Research (CBER) at the FDA. Modernal stock fell 12%, Sarepta Therapeutics (NASDAQ:SRPT) shares dropped 25%, Capricor Therapeutics (NASDAQ:CAPR) plummeted 24%, and Arcellx declined by 16%.
investing.com·4mo ago
News Placeholder
Futures Flat As Geopolitical Tensions Offset Latest China Stimulus Vows
Futures Flat As Geopolitical Tensions Offset Latest China Stimulus Vows S&P futures are flat after hitting a fresh record highs on Friday and ceding brief gains sparked by China's...
Zero Hedge·9mo ago
News Placeholder
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...
Business Wire·9mo ago
News Placeholder
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...
Business Wire·10mo ago
News Placeholder
Navigating 7 Analyst Ratings For Arcellx
Latest Ratings for ACLX DateFirmActionFromTo Mar 2022SVB LeerinkInitiates Coverage OnOutperform Mar 2022B of A SecuritiesInitiates Coverage OnBuy View More Analyst Ratings for ACLX...
Benzinga·10mo ago
News Placeholder
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...
Business Wire·10mo ago
News Placeholder
4 Analysts Assess Arcellx: What You Need To Know
Latest Ratings for ACLX DateFirmActionFromTo Mar 2022SVB LeerinkInitiates Coverage OnOutperform Mar 2022B of A SecuritiesInitiates Coverage OnBuy View More Analyst Ratings for ACLX...
Benzinga·11mo ago

Latest ACLX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.